The estimated Net Worth of Christopher S Henney is at least $421 Thousand dollars as of 14 July 2021. Christopher Henney owns over 11,108 units of Prothena plc stock worth over $232,490 and over the last 21 years he sold PRTA stock worth over $0. In addition, he makes $188,444 as Independent Director at Prothena plc.
Christopher has made over 14 trades of the Prothena plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 11,108 units of PRTA stock worth $125,854 on 14 July 2021.
The largest trade he's ever made was buying 25,324 units of Prothena plc stock on 30 January 2017 worth over $104,082. On average, Christopher trades about 2,100 units every 37 days since 2003. As of 14 July 2021 he still owns at least 11,108 units of Prothena plc stock.
You can see the complete history of Christopher Henney stock trades at the bottom of the page.
Dr. Christopher S. Henney Ph.D. serves as Independent Director of the Company. He is Vice-Chairman of the Board of Cyclacel Pharmaceuticals, Inc. Inc. From 1995 to 2004, he served as Chairman of the Board and Chief Executive Officer of Dendreon Corporation, a biotechnology company that he co-founded. Dr. Henney also co-founded and served as a director and in executive positions at Immunex Corporation and ICOS Corporation (both biotechnology companies). He was Chairman of the Board of Cascadian Therapeutics, Inc. (a biotechnology company) from 2006 to 2018, where he also served as interim President and Chief Executive Officer for part of 2016, and served as a director of Anthera Pharmaceuticals, Inc. (a biopharmaceutical company) from 2008 to 2018. Dr. Henney is a 2011 inductee to The Biotechnology Hall of Fame. He earned his B.Sc. in medical biochemistry, his Ph.D. in experimental pathology and his D.Sc. for contributions to the field of immunology from the University of Birmingham, England. Dr. Henney has served on our Board since 2013.
As the Independent Director of Prothena plc, the total compensation of Christopher Henney at Prothena plc is $188,444. There are 17 executives at Prothena plc getting paid more, with Wagner Zago having the highest compensation of $3,341,640.
Christopher Henney is 78, he's been the Independent Director of Prothena plc since 2013. There are no older and 24 younger executives at Prothena plc.
Christopher's mailing address filed with the SEC is C/O CYCLACEL PHARMACEUTICALS, INC.,, 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S..., and Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: